Nurix begins investor meetings with updated clinical plans for bexobrutideg Phase 1 trial

Nurix Therapeutics, Inc.

Company presenting updated development plans for bexobrutideg (NX-5948), an oral BTK degrader.
Phase 1 trial ongoing in patients with relapsed/refractory B cell malignancies.
Investor presentation dated September 3, 2025, furnished as Exhibit 99.1.
Specific clinical data updates not detailed in the 8-K filing text.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.